• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.

作者信息

Sia Daniela, Llovet Josep M

机构信息

Mount Sinai Liver Cancer Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York 10029, USA.

Mount Sinai Liver Cancer Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York 10029, USA; at the Liver Cancer Translational Research Laboratory, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Univesitat de Barcelona, Rosselló 153, Barcelona 08039, Spain; and at the Institució Catalana de Recerca i Estudis Avançats, Passeig de Lluís Companys 23, Barcelona 08010, Spain.

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):571-572. doi: 10.1038/nrgastro.2017.103. Epub 2017 Aug 2.

DOI:10.1038/nrgastro.2017.103
PMID:28765583
Abstract
摘要

相似文献

1
Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.肝癌：将“组学”结果转化为肝细胞癌的精准医学
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):571-572. doi: 10.1038/nrgastro.2017.103. Epub 2017 Aug 2.
2
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?肝细胞癌：循环肿瘤细胞和放射基因组学能否提供个性化医疗？
Am J Clin Oncol. 2015 Aug;38(4):431-6. doi: 10.1097/COC.0000000000000123.
3
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.肝细胞癌的分子分型：迈向精准医学的一步。
Cancer Commun (Lond). 2020 Dec;40(12):681-693. doi: 10.1002/cac2.12115. Epub 2020 Dec 8.
4
Multiplatform Genomic Roadmap of Hepatocellular Carcinoma: A Matter of Molecular Heterogeneity.肝细胞癌的多平台基因组路线图：分子异质性问题
Hepatology. 2018 Nov;68(5):2029-2032. doi: 10.1002/hep.29925. Epub 2018 Sep 24.
5
Hepatocellular carcinoma in 2011: Genomics in hepatocellular carcinoma--a big step forward.2011年肝细胞癌：肝细胞癌的基因组学——向前迈进一大步。
Nat Rev Gastroenterol Hepatol. 2012 Jan 10;9(2):69-70. doi: 10.1038/nrgastro.2011.255.
6
[Molecular prediction of metastatic recurrence of hepatocellular carcinoma: from-omics to clinical application].[肝细胞癌转移复发的分子预测：从组学到临床应用]
Zhonghua Wai Ke Za Zhi. 2012 Jan 1;50(1):1-3.
7
Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.致编辑的信：基于多组学的分子分类有助于肝细胞癌的预后分层和个性化治疗。
Hepatology. 2024 Oct 1;80(4):E58-E59. doi: 10.1097/HEP.0000000000000944. Epub 2024 May 28.
8
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma.用于肝细胞癌个性化靶向治疗的细胞系基因组分析
Hepatology. 2013 Dec;58(6):2207. doi: 10.1002/hep.26407. Epub 2013 Oct 10.
9
Genomic decoding of hepatocellular carcinoma.肝细胞癌的基因组解码
Gastroenterology. 2006 Oct;131(4):1344-6. doi: 10.1053/j.gastro.2006.08.060.
10
Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study.利用多组学策略对个性化候选突变驱动基因进行优先级排序：一项概念验证研究。
Sci Rep. 2015 Dec 3;5:17564. doi: 10.1038/srep17564.

引用本文的文献

1
Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.肝癌中的新型基因改变可区分不同的临床结局和联合免疫治疗反应。
Front Pharmacol. 2024 Jun 14;15:1416295. doi: 10.3389/fphar.2024.1416295. eCollection 2024.
2
Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.肝细胞癌：分子分类和精准肿瘤学的过去、现在的挑战与进展。
Int J Mol Sci. 2023 Aug 26;24(17):13274. doi: 10.3390/ijms241713274.
3
Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.

本文引用的文献

1
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.基于分子特征鉴定免疫特异的肝细胞癌。
Gastroenterology. 2017 Sep;153(3):812-826. doi: 10.1053/j.gastro.2017.06.007. Epub 2017 Jun 15.
2
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.肝细胞癌的综合与整合基因组特征分析
Cell. 2017 Jun 15;169(7):1327-1341.e23. doi: 10.1016/j.cell.2017.05.046.
3
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
超重/肥胖相关的转录组特征与肝细胞癌的临床结局、免疫微环境和治疗反应相关。
Front Endocrinol (Lausanne). 2023 Jan 12;13:1061091. doi: 10.3389/fendo.2022.1061091. eCollection 2022.
4
Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma.三维（3D）细胞培养：推进人类肝细胞癌治疗的重要一步。
Cancer Cell Int. 2022 Jul 30;22(1):243. doi: 10.1186/s12935-022-02662-3.
5
The advanced development of molecular targeted therapy for hepatocellular carcinoma.肝细胞癌的分子靶向治疗的进展。
Cancer Biol Med. 2022 Jun 15;19(6):802-17. doi: 10.20892/j.issn.2095-3941.2021.0661.
6
DNTTIP1 is a Prognostic Biomarker Correlated With Immune Infiltrates in Hepatocellular Carcinoma: A Study Based on The Cancer Genome Atlas Data.DNTTIP1是一种与肝细胞癌免疫浸润相关的预后生物标志物：基于癌症基因组图谱数据的研究
Front Genet. 2022 Feb 21;12:767834. doi: 10.3389/fgene.2021.767834. eCollection 2021.
7
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.肝细胞癌的分子分型：迈向精准医学的一步。
Cancer Commun (Lond). 2020 Dec;40(12):681-693. doi: 10.1002/cac2.12115. Epub 2020 Dec 8.
8
Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.胃肠道的表观遗传学改变：癌症生物标志物的当前和新兴用途。
Gastroenterology. 2021 Feb;160(3):690-709. doi: 10.1053/j.gastro.2020.09.058. Epub 2020 Dec 3.
9
Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.肝细胞癌诊断和预后新型生物标志物的鉴定与验证
Front Oncol. 2020 Sep 25;10:541479. doi: 10.3389/fonc.2020.541479. eCollection 2020.
10
New Therapeutic Targets in Autoimmune Cholangiopathies.自身免疫性胆管病的新治疗靶点
Front Med (Lausanne). 2020 Apr 7;7:117. doi: 10.3389/fmed.2020.00117. eCollection 2020.
纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
4
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.肝癌细胞起源、分子亚型及其对患者预后的影响。
Gastroenterology. 2017 Mar;152(4):745-761. doi: 10.1053/j.gastro.2016.11.048. Epub 2016 Dec 30.
5
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
6
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.
7
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.肝细胞癌的遗传景观和生物标志物。
Gastroenterology. 2015 Oct;149(5):1226-1239.e4. doi: 10.1053/j.gastro.2015.05.061. Epub 2015 Jun 20.
8
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.肝细胞癌的外显子组测序鉴定出新的突变特征和潜在治疗靶点。
Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.
9
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.跨种族肝细胞癌基因组的突变特征。
Nat Genet. 2014 Dec;46(12):1267-73. doi: 10.1038/ng.3126. Epub 2014 Nov 2.
10
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.